Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aim...
Gespeichert in:
| Veröffentlicht in: | Malaysian journal of pathology 2024-12, Vol.46 (3), p.431 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 431 |
| container_title | Malaysian journal of pathology |
| container_volume | 46 |
| creator | Yusoff, Y M Seman, Z A Anoar, S Z Said, S S M Azman, N Kamaluddin, N R Abdullah, J Yacob, S S M Esa, E |
| description | The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.
Twenty three CML patients (26.7%) showed to have BCR:ABL1 KD mutations with IM resistance.
A total of 14 different types of mutations were identified which are Y253H, E255K, T267A, A287T, M290R, F3111, T3151, F317L, F359V, F3591, F359C, K357T, A399T, E459K and two novel mutations; M290R and K357T. We also discovered two silent mutations at codons 389 and 401.
Mutational analysis is recommended to identify patients at risk of disease progression. Therefore, early detection of such mutations may allow timely treatment intervention to prevent or overcome resistance. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3149881028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3149881028</sourcerecordid><originalsourceid>FETCH-LOGICAL-p562-bc00936b441c02788e9df6c8fb29dfeb79e89a74b47edb57fbb8ddb945e0e0a33</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRb0A0VL4BeQlm0hO7CR2d23Fo1IlJNR95MdENY3tECegip_HqGV1z-LM6OpeoTnJiyrjFS1n6DbGD0IqJgS_QTMqapozUczRz9aAH21rtRxt8Di02Icv6PB6875crta7HB-tlxGwCU5aj900ns3EfaJ0HfG3HQ9YH4bgrcbuBF2wBncwHSU4K7H0BluXZG8VHiDaOEqv4Q5dt7KLcH_JBdo_P-03r9nu7WW7We2yvqyKTGlCBK0UY7kmRc05CNNWmreqSACqFsCFrJliNRhV1q1S3BglWAkEiKR0gR7Pb_shfE4Qx8bZqKHrpIcwxeZvCc5zUvCkPlzUSTkwTT-k2sOp-d-L_gK8v2g1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149881028</pqid></control><display><type>article</type><title>Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Yusoff, Y M ; Seman, Z A ; Anoar, S Z ; Said, S S M ; Azman, N ; Kamaluddin, N R ; Abdullah, J ; Yacob, S S M ; Esa, E</creator><creatorcontrib>Yusoff, Y M ; Seman, Z A ; Anoar, S Z ; Said, S S M ; Azman, N ; Kamaluddin, N R ; Abdullah, J ; Yacob, S S M ; Esa, E</creatorcontrib><description>The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.
Twenty three CML patients (26.7%) showed to have BCR:ABL1 KD mutations with IM resistance.
A total of 14 different types of mutations were identified which are Y253H, E255K, T267A, A287T, M290R, F3111, T3151, F317L, F359V, F3591, F359C, K357T, A399T, E459K and two novel mutations; M290R and K357T. We also discovered two silent mutations at codons 389 and 401.
Mutational analysis is recommended to identify patients at risk of disease progression. Therefore, early detection of such mutations may allow timely treatment intervention to prevent or overcome resistance.</description><identifier>ISSN: 0126-8635</identifier><identifier>PMID: 39731492</identifier><language>eng</language><publisher>Malaysia</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents - therapeutic use ; DNA Mutational Analysis ; Drug Resistance, Neoplasm - genetics ; Female ; Fusion Proteins, bcr-abl - genetics ; Humans ; Imatinib Mesylate - therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Male ; Middle Aged ; Mutation ; Protein Kinase Inhibitors - therapeutic use ; Young Adult</subject><ispartof>Malaysian journal of pathology, 2024-12, Vol.46 (3), p.431</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39731492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yusoff, Y M</creatorcontrib><creatorcontrib>Seman, Z A</creatorcontrib><creatorcontrib>Anoar, S Z</creatorcontrib><creatorcontrib>Said, S S M</creatorcontrib><creatorcontrib>Azman, N</creatorcontrib><creatorcontrib>Kamaluddin, N R</creatorcontrib><creatorcontrib>Abdullah, J</creatorcontrib><creatorcontrib>Yacob, S S M</creatorcontrib><creatorcontrib>Esa, E</creatorcontrib><title>Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance</title><title>Malaysian journal of pathology</title><addtitle>Malays J Pathol</addtitle><description>The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.
Twenty three CML patients (26.7%) showed to have BCR:ABL1 KD mutations with IM resistance.
A total of 14 different types of mutations were identified which are Y253H, E255K, T267A, A287T, M290R, F3111, T3151, F317L, F359V, F3591, F359C, K357T, A399T, E459K and two novel mutations; M290R and K357T. We also discovered two silent mutations at codons 389 and 401.
Mutational analysis is recommended to identify patients at risk of disease progression. Therefore, early detection of such mutations may allow timely treatment intervention to prevent or overcome resistance.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>DNA Mutational Analysis</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Female</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Humans</subject><subject>Imatinib Mesylate - therapeutic use</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Young Adult</subject><issn>0126-8635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAQRb0A0VL4BeQlm0hO7CR2d23Fo1IlJNR95MdENY3tECegip_HqGV1z-LM6OpeoTnJiyrjFS1n6DbGD0IqJgS_QTMqapozUczRz9aAH21rtRxt8Di02Icv6PB6875crta7HB-tlxGwCU5aj900ns3EfaJ0HfG3HQ9YH4bgrcbuBF2wBncwHSU4K7H0BluXZG8VHiDaOEqv4Q5dt7KLcH_JBdo_P-03r9nu7WW7We2yvqyKTGlCBK0UY7kmRc05CNNWmreqSACqFsCFrJliNRhV1q1S3BglWAkEiKR0gR7Pb_shfE4Qx8bZqKHrpIcwxeZvCc5zUvCkPlzUSTkwTT-k2sOp-d-L_gK8v2g1</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Yusoff, Y M</creator><creator>Seman, Z A</creator><creator>Anoar, S Z</creator><creator>Said, S S M</creator><creator>Azman, N</creator><creator>Kamaluddin, N R</creator><creator>Abdullah, J</creator><creator>Yacob, S S M</creator><creator>Esa, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202412</creationdate><title>Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance</title><author>Yusoff, Y M ; Seman, Z A ; Anoar, S Z ; Said, S S M ; Azman, N ; Kamaluddin, N R ; Abdullah, J ; Yacob, S S M ; Esa, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p562-bc00936b441c02788e9df6c8fb29dfeb79e89a74b47edb57fbb8ddb945e0e0a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>DNA Mutational Analysis</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Female</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Humans</topic><topic>Imatinib Mesylate - therapeutic use</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yusoff, Y M</creatorcontrib><creatorcontrib>Seman, Z A</creatorcontrib><creatorcontrib>Anoar, S Z</creatorcontrib><creatorcontrib>Said, S S M</creatorcontrib><creatorcontrib>Azman, N</creatorcontrib><creatorcontrib>Kamaluddin, N R</creatorcontrib><creatorcontrib>Abdullah, J</creatorcontrib><creatorcontrib>Yacob, S S M</creatorcontrib><creatorcontrib>Esa, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Malaysian journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yusoff, Y M</au><au>Seman, Z A</au><au>Anoar, S Z</au><au>Said, S S M</au><au>Azman, N</au><au>Kamaluddin, N R</au><au>Abdullah, J</au><au>Yacob, S S M</au><au>Esa, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance</atitle><jtitle>Malaysian journal of pathology</jtitle><addtitle>Malays J Pathol</addtitle><date>2024-12</date><risdate>2024</risdate><volume>46</volume><issue>3</issue><spage>431</spage><pages>431-</pages><issn>0126-8635</issn><abstract>The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.
Twenty three CML patients (26.7%) showed to have BCR:ABL1 KD mutations with IM resistance.
A total of 14 different types of mutations were identified which are Y253H, E255K, T267A, A287T, M290R, F3111, T3151, F317L, F359V, F3591, F359C, K357T, A399T, E459K and two novel mutations; M290R and K357T. We also discovered two silent mutations at codons 389 and 401.
Mutational analysis is recommended to identify patients at risk of disease progression. Therefore, early detection of such mutations may allow timely treatment intervention to prevent or overcome resistance.</abstract><cop>Malaysia</cop><pmid>39731492</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0126-8635 |
| ispartof | Malaysian journal of pathology, 2024-12, Vol.46 (3), p.431 |
| issn | 0126-8635 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3149881028 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Adolescent Adult Aged Antineoplastic Agents - therapeutic use DNA Mutational Analysis Drug Resistance, Neoplasm - genetics Female Fusion Proteins, bcr-abl - genetics Humans Imatinib Mesylate - therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Male Middle Aged Mutation Protein Kinase Inhibitors - therapeutic use Young Adult |
| title | Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T16%3A29%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20novel%20BCR::ABL1%20kinase%20domain%20mutation%20in%20patients%20with%20chronic%20myeloid%20leukaemia%20and%20imatinib%20resistance&rft.jtitle=Malaysian%20journal%20of%20pathology&rft.au=Yusoff,%20Y%20M&rft.date=2024-12&rft.volume=46&rft.issue=3&rft.spage=431&rft.pages=431-&rft.issn=0126-8635&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E3149881028%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3149881028&rft_id=info:pmid/39731492&rfr_iscdi=true |